晚期胃癌不同一线及后线治疗方案的疗效对比分析
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2022年22期
- 页码:
- 4113-4119
- 栏目:
- 论著（消化肿瘤）
- 出版日期:
- 2022-10-12
文章信息/Info
- Title:
- Comparison of the efficacy of different first-line and posterior-line treatment regimens for advanced gastric cancer
- Author(s):
- ZHANG Liping; ZHAO Yuanyuan; YU Xihe; WANG Aijing; LIN Hui; ZHANG Qizhou
- Department of Oncology,Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine,Guangdong Foshan 528200,China.
- Keywords:
- advanced gastric cancer; chemotherapy; PFS; OS
- 分类号:
- R735.2
- DOI:
- 10.3969/j.issn.1672-4992.2022.22.017
- 文献标识码:
- A
- 摘要:
- 目的：分析晚期胃癌（advanced gastric cancer,AGC）一线及后线治疗方案的疗效及生存情况，为指导AGC的系统治疗及全程管理提供依据。方法：收集我院肿瘤科2015年01月至2019年12月收治的AGC患者的临床特征、辅助检查资料、治疗相关资料、疗效评估、疾病转归等相关临床资料，建立数据库，分析不同一线及后线治疗方案的疗效，以及不同人群、进行不同线数化疗的患者总生存期（overall survival,OS）的差异。结果：一线治疗总体客观缓解率(objective response rate,ORR)为37.6%，疾病控制率(disease control rate,DCR)为83.9%；二线治疗ORR为9.5%，DCR为44.6%；三线及以上治疗ORR为0%，DCR为15.2%。总体人群一线治疗中位无进展生存(median progression-free survival,mPFS)时间为7.0个月，中位总生存(median overall survival,mOS)时间为15.6个月；二线治疗mPFS时间为3.0个月，mOS时间为7.2个月。一线化疗采取含铂方案与含紫杉方案对比，mPFS分别为7.0个月、4.5个月（P=0.041），mOS分别为16.0个月、9.0个月（P=0.061）；二线含紫杉方案与含伊立替康方案对比，mPFS分别为2.6个月、4.0个月（P=0.531），mOS分别为7.0个月、6.5个月（P=0.822）。仅进行一线治疗、一线+二线治疗、一线+二线+三线及以上治疗的AGC患者mOS分别为14.0个月、14.0个月及20.0个月，进行三线及以上治疗的患者mOS优于进行一线+二线治疗的患者（P=0.001）。一线方案中采用两药或三药及以上、有无免疫治疗对患者的mPFS及mOS无影响，且二线治疗中有无联合免疫治疗对患者的mPFS及mOS也无影响。结论：含铂双药方案疗效较佳，应作为AGC患者一线治疗的优选方案；二线及后线化疗有效率较低，二线化疗方案紫杉类与伊立替康疗效无差异；在非选择AGC人群中，一线及二线治疗中联合免疫治疗未见改善生存，化疗仍然是基石。
- Abstract:
- Objective：To investigate the efficacy and survival time of first-line and posterior-line treatment for advanced gastric cancer (AGC),so as to provide basis for systematic treatment and full treatment management to AGC.Methods:The clinical characteristics,auxiliary examination data,treatment-related data,curative effect evaluation,disease outcome and other related clinical data of patients with AGC admitted to the department of oncology in our hospital from January 2015 to December 2019 were collected,and the database was established to analyze the efficacy of different first-line and posterior-line treatment regimens,as well as the difference of overall survival (OS) time of patients with different groups and different lines of chemotherapy.Results:The objective response rate (ORR) of first-line treatment was 37.6%,and the disease control rate (DCR) was 83.9%.The ORR of second-line treatment was 9.5%,and the DCR was 44.6%.The ORR of third-line and above treatment was 0%,and the DCR was 15.2%.In the total population,the median progression-free survival (mPFS) and median OS (mOS) of the first-line treatment were 7.0 months and 15.6 months,while the mPFS and mOS of the second-line treatment were 3.0 months and 7.2 months respectively.Compared with the regimen containing platinum and taxanes in the first-line chemotherapy,the mPFS was 7.0 months and 4.5 months respectively (P=0.041),mOS was 16.0 months and 9.0 months respectively （P=0.061）.The mPFS of the second-line regimen containing taxanes and irinotecan was 2.6 months and 4.0 months respectively (P=0.531),mOS was 7.0 months and 6.5 months respectively (P=0.822).The mOS of patients with AGC who received only first-line therapy,first-line＋second-line therapy,third-line and more were 14.0,14.0 and 20.0 months,respectively.The mOS time of patients received third-line and more treatment was better than that of patients with first-line＋second-line therapy (P=0.001).In the first-line regimen,chemotherapy with two or three drugs or more,also with or without immunotherapy had no effect on prolonging the mPFS time and mOS time of the AGC patients,and the combination of immunotherapy in the second-line therapy showed no effect on the mPFS and mOS.Conclusion:Platinum-containing doublet chemotherapy is effective and should be used as the optimal regimen for first-line treatment of AGC.The effective rate of second-line and posterior-line chemotherapy is low,and there is no differences between taxanes and irinotecan in the second-line chemotherapy.In non-selected patients with AGC,combined immunotherapy in first-line and second-line treatment did not improve overall survival,and chemotherapeutic drugs were pivotal in AGC patients.
参考文献/References
［1］FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods［J］.Int J Cancer,2019,144(8):1941-1953.
[2]WAGNER AD,SYN NL,MOEHLER M,et al.Chemotherapy for advanced gastric cancer［J］.Cochrane Database Syst Rev,2017,8:D4064.
[3]GLIMELIUS B,EKSTROM K,HOFFMAN K,et al.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer［J］.Ann Oncol,1997,8(2):163-168.
[4]BANG YJ,VAN CUTSEM E,FEYEREISLOVA A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label,randomised controlled trial［J］.Lancet,2010,376(9742):687-697.
[5]FUCHS CS,TOMASEK J,YONG CJ,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international,randomised,multicentre,placebo-controlled,phase 3 trial［J］.Lancet,2014,383(9911):31-39.
[6]JANMAAT VT,STEYERBERG EW,VAN DER GAAST A,et al.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer［J］.Cochrane Database Syst Rev,2017,11:D4063.
[7]KOIZUMI W,NARAHARA H,HARA T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial［J］.The Lancet Oncology,2008,9(3):215-221.
[8]KANG YK,KANG WK,SHIN DB,et al.Capecitabine/cisplatin versus 5-fluorouracil/cisplatinas first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferioritytrial［J］.Annals of Oncology,2009,20(4):666.
[9]VAN CUTSEM E,MOISEYENKO VM,TJULANDIN S,et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group［J］.Journal of Clinical Oncology,2006,24(31):4991-4997.
[10]GUO X,ZHAO F,MA X,et al.A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis［J］.BMC Cancer,2019,19(1):1125.
[11]BANDO H,SHIMODAIRA H,FUJITANI K,et al.A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer［J］.Eur J Cancer,2018,91:86-91.
[12]THUSS-PATIENCE PC,KRETZSCHMAR A,BICHEV D,et al.Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)［J］.Eur J Cancer,2011,47(15):2306-2314.
[13]FORD HE,MARSHALL A,BRIDGEWATER JA,et al.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label,phase 3 randomised controlled trial［J］.Lancet Oncol,2014,15(1):78-86.
[14]FANOTTO V,UCCELLO M,PECORA I,et al.Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy［J］.Oncologist,2017,22(12):1463-1469.
[15]ZHANG Y,HAN C,LI J,et al.Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study［J］.Sci Rep,2017,7(1):13208.
[16]SHITARA K,DOI T,DVORKIN M,et al.Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2018,19(11):1437-1448.
[17]CHUA TC,MERRETT ND.Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review［J］.Int J Cancer,2012,130(12):2845-2856.
[18]GOMEZ-MARTIN C,GARRALDA E,ECHARRI MJ,et al.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer［J］.J Clin Pathol,2012,65(8):751-757.
[19]SHENG WQ,HUANG D,YING JM,et al.HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance［J］.Annals of Oncology,2013,24(9):2360-2364.
[20]HUANG D,LU N,FAN Q,et al.HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study［J］.PLoS One,2013,8(11):e80290.
[21]JANJIGIAN YY,MARON SB,CHATILA WK,et al.First-line pembrolizumab and trastuzumab in HER2-positive oesophageal,gastric,or gastro-oesophageal junction cancer: an open-label,single-arm,phase 2 trial［J］.Lancet Oncol,2020,21(6):821-831.
[22]SONG C,SHAH MA,WU H,et al.Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind,randomised,placebo-controlled phase 3 study［J］.The Lancet Oncology,2018,19(10):1372-1384.
[23]THUSS-PATIENCE PC,SHAH MA,OHTSU A,et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised,open-label,adaptive,phase 2/3 study［J］.The Lancet Oncology,2017,18(5):640-653.
[24]SHAH MA,KANG YK,THUSS-PATIENCE PC,et al.Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer［J］.Gastric Cancer,2019,22(4):803-816.
[25]MAKIYAMA A,SUKAWA Y,KASHIWADA T,et al.Randomized,phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study)［J］.J Clin Oncol,2020,38(17):1919-1927.
[26]FUCHS CS,DOI T,JANG RW.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial (vol 4,e180013,2018)［J］.JAMA Oncology,2019,5(4):579.
[27]SHITARA K,OZGUROGLU M,BANG YJ,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised,open-label,controlled,phase 3 trial［J］.Lancet,2018,392(10142):123-133.
[28]KANG YK,BOKU N,SATOH T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens (ONO-4538-12,ATTRACTION-2): a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet,2017,390(10111):2461-2471.
[29]BOKU N,RYU MH,KATO K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized,phase II trial (ATTRACTION-4)［J］.Ann Oncol,2019,30(2):250-258.
[30]WANG F,WEI XL,WANG FH,et al.Safety,efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab,a PD-1 antibody in phase Ib/II clinical trial NCT02915432［J］.Ann Oncol,2019,30(9):1479-1486.
备注/Memo
- 备注/Memo:
- -
